Jaguar Health, Inc..
JAGX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing novel, plant-based, non-opioid prescription medicines for people and animals with gastrointestinal distress, specifically chronic diarrhea. The company's human health product is Mytesi® (crofel...Show More
Better Health for All
-30
Jaguar Health's core products and pipeline are entirely focused on health benefits, including FDA-approved Mytesi for HIV/AIDS-related diarrhea, conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and pipeline candidates for cancer therapy-related diarrhea, short bowel syndrome, microvillus inclusion disease, and infectious diarrhea.
1
The company also has a 40% ownership stake in Magdalena Biosciences, which develops plant-based drugs for mental health.
2
Mytesi has been commercialized since 2012 with no reported serious adverse events,
3
though common adverse reactions like upper respiratory tract infection (5.7-6%) and bronchitis (3.9-4%) were observed in clinical studies.
4
However, the price of Mytesi increased nearly threefold from $688.52 to $2,206.52 per bottle in early April, leading to concerns from US Representatives about accessibility.
5
The company offers a copay savings program (up to $6,000 annually) and a patient assistance program for uninsured patients.
6
Jaguar Health's R&D expenses were $17.6 million in 2022.
7
Crofelemer is derived from sustainably harvested plants from rainforest areas, and Napo Pharmaceuticals has established fair trade practices supporting indigenous communities.
8
Jaguar Health launched the Entheogen Therapeutics Initiative in 2021 and formed Magdalena Biosciences in 2023 to develop plant-based mental health drugs.
9
The company's Code of Business Conduct and Ethics, effective May 2015, outlines expectations for data confidentiality and regulatory compliance.
10
Crofelemer is non-opioid, and Magdalena Biosciences is developing non-stimulant ADHD drugs.
11
Jaguar Health chairs an ETI Ethics Board to ensure ethical standards regarding traditional knowledge and fair benefit-sharing.
12
Fair Money & Economic Opportunity
0
No evidence available to assess Jaguar Health, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific quantitative data was found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While executive compensation figures were available for the CEO and other officers, there was no information on median employee compensation to calculate the CEO to median pay ratio.
1
Qualitative statements from employee reviews indicated a "high employee turnover rate" and a "toxic work atmosphere," but no numerical turnover rate or employee engagement score was provided.
2
Similarly, there was no data on living wage coverage, collective bargaining share, safety incident rates, pay equity ratios, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Jaguar Health, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
Jaguar Health, Inc. has a confidential, anonymous, and independent 24/7 whistleblower hotline and a secure web form, with a tracking code provided for messages.
1
The company explicitly prohibits retaliation against individuals who report violations in good faith, and training on the anti-bribery and anti-corruption policy is part of the onboarding process for all new employees and directors.
2
The company has a material weakness in its internal control over financial reporting related to income taxes.
3
It has undergone five reverse stock splits between 2018 and 2024.
4
The Code of Business Conduct and Ethics requires full compliance with the Foreign Corrupt Practices Act (FCPA) and prohibits payments intended to improperly influence business decisions.
5
The board of directors periodically reviews its composition and the independence of its directors.
6
However, the median time to close customer or stakeholder ethics complaints is not provided, and the company has not disclosed any specific resolution times for complaints.
Kind to Animals
-50
Jaguar Health, Inc. conducts preclinical studies and field studies in animals, including dogs and racehorses, for drug development and regulatory approval, with no evidence of employing non-animal testing methods.
1
The company completed a study in 200 dogs with general diarrhea and is conducting a field study of Canalevia-CA1 in dogs undergoing chemotherapy treatment across the U.S., with enrollment reaching 25%.
2
The company's animal testing policy prohibits discretionary testing, but legal mandates for animal testing still override alternatives. The company's products, such as crofelemer, are plant-based, meaning there are zero animal inputs.
3
Jaguar Health works with the FDA to obtain full approval for Canalevia and has received Minor Use in a Major Species (MUMS) designation for Canalevia-CA1 to treat chemotherapy-induced diarrhea in dogs, which indicates engagement with regulatory bodies but not active advocacy for higher animal welfare standards.
4
No War, No Weapons
0
No specific evidence was found in the provided articles regarding Jaguar Health, Inc.'s (JAGX.US) involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' ethical value. pertains to a different company (JX Advanced Metals Corporation).
1
Articles and explicitly state that no quantitative data or relevant information for JAGX.US on these metrics is provided.
2
3
Planet-Friendly Business
-80
Jaguar Health mentions sustainable harvesting practices for the plant material used in its products, such as crofelemer and Canalevia, which are derived from the Croton lechleri tree in the Amazon rainforest.
1
The company has partnerships with local communities and established a non-profit, the Healing Forest Conservancy, to support these efforts.
2
However, no specific quantitative data on the scale or outcomes of these biodiversity programs is provided, nor is there a formal deforestation policy or verified implementation details across its supply chain.
3
The company's 2023 Form 10-K mentions evolving ESG expectations and the potential for increased regulatory scrutiny, but does not provide TCFD disclosures, climate scenario analysis, or transparency regarding stranded asset risks.
4
There is no mention of climate justice, just transition, or climate adaptation financing programs.
5
The company has not reported any environmental compliance violations.
6
Respect for Cultures & Communities
0
No evidence available to assess Jaguar Health, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company provides users with standard options to limit data sharing for targeted advertising and allows requests for data access, deletion, and correction.
1
It also generally mentions compliance with legal requirements regarding privacy, without specifying particular regulations or audit results.
2
Zero Waste & Sustainable Products
0
No evidence available to assess Jaguar Health, Inc. on Zero Waste & Sustainable Products.